Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.31 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3685331 | 0.85 | KDM4E (0.32) | ACACBKDM4EALDH1A1LMNAL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL3685324 | 0.85 | KDM4E (0.32) | ACACBKDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL13410034 | 0.85 | KDM4E (0.37) | ACACBKDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL3688358 | 0.84 | CRAT (0.40) | ACACBKDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL3688363 | 0.84 | CRAT (0.40) | ACACBKDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL3682524 | 0.83 | ACACB (0.35) | ACACBKDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL3687517 | 0.83 | ACACB (0.35) | ACACBKDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL3679969 | 0.82 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL3688863 | 0.81 | NPC1 (0.31) | ALDH1A1 | |
| SCHEMBL3685222 | 0.79 | CPT2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | claimed |
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | ACACB 50/4885KDM4E 1405/4885ALDH1A1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.